PHOTON-2: Hope for patients with HIV and HCV co-infection?

The Lancet

Volumn 385, Issue 9973, 2015, Pages 1052-1054

  Naggie, Susanna ^a   Kim, Arthur Y ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DASABUVIR; INTERFERON; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE; VIRUS RNA;

ANTIVIRAL THERAPY; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; NOTE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; FEMALE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MALE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; RIBAVIRIN; RNA, VIRAL; URIDINE MONOPHOSPHATE;

EID: 84925658477     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60122-2     Document Type: Note

References (14)

1. MJ Alter Epidemiology of viral hepatitis and HIV co-infection J Hepatol 44 suppl 2006 S6 S9
2. J Berenguer, J Alvarez-Pellicer, PM Martin et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 2009 407 413
3. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Guidance for industry. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm225333.pdf October, 2013 (accessed Jan 14, 2015).
4. MS Sulkowski, S Naggie, J Lalezari et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection JAMA 312 2014 353 361
5. J-M Molina, C Orkin, DM Iser for the PHOTON-2 study team Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study Lancet 2015 published online Feb 4. http://dx.doi.org/10.1016/S0140-6736(14)62483-1
6. IM Jacobson, SC Gordon, KV Kowdley et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
7. E Lawitz, A Mangia, D Wyles et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
8. D Dieterich, JK Rockstroh, C Orkin et al. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study Clin Infect Dis 59 2014 1579 1587
9. Townsend KS, Osinusi A, Nelson AK, et al. High efficacy of sofosbuvir/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on or off antiretroviral therapy: results from the NIAID ERADICATE trial. American Association for the Study of Liver Diseases (AASLD) Liver Meeting; Boston, MA; Nov 7-11, 2014. 84 (abstr).
10. Wyles D, Sulkowski M, Eron JJ, et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2014; Boston. MA; Nov 7-11, 2014. 1939 (abstr).
11. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 2014 392 420
12. American Association for the Study of Liver Disease Infectious Diseases Society of America International Antiviral Society - USA Recommendations for testing, managing, and treating hepatitis C http://hcvguidelines.org/ (accessed Jan 14, 2015).
13. Gilead Sciences Harvoni (package insert) 2014 Gilead Sciences Foster City, CA
14. AbbVie Viekira Pak (package insert) 2014 AbbVie North Chicago, IL